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Abstract β-catenin and E cadherin are both membrane-
associated proteins which are essential regulators and providers
of cellular adhesion. In the metastatic cascade of malignant
tumours, detachment of tumour cells from each other is a very
important step. It has been shown in several tumour types, that
reduced expression of these proteins is important. The aim of
our study was to clarify the expression profile of these proteins,
and correlate the findings with the metastasizing potential of
early stage colon and rectal cancers. Formalin fixed and paraffin
embedded samples from 79 Dukes B2 stage colorectal cancer
were examined using a tissue microarray approach. The
expression ofβ-catenin and E-cadherin proteins was determined
immunohistochemically. Our findings indicated that there is a
tendency for metastatic spread in cases when membranous
expression of β-catenin is lost (p=0.062). Similarly metastases
in negative cases developed more rapidly, than in positive ones
(p=0.05). Survival rate was worse in the negative cases. The
risk of metastasis in rectal cancer was significantly higher in
the β-catenin membranously negative than positive groups
(p=0.024) and in case of β-catenin nuclear expression the risk
was also higher (p=0.047). Reduced E-cadherin expression
also correlated with development of metastatic disease, but this
association was statistically not significant. The immunohisto-
chemical analysis of 79 cases shows that in Dukes B2 stage
colorectal tumours clarification of β-catenin and E-cadherin
expression patterns is reliable for predicting the metastatic
potential of early stage rectal cancer and hence the method
may have relevant implications in the therapeutic management
of these cancers.
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Introduction
Colorectal cancer is estimated to be the second leading cause
of cancer death worldwide [1]. Currently, selected therapy
and identification of prognostic groups are based on classical
clinicopathologic data, i. e., tumour grade and stage.
However, Dukes B2 stage patients exhibit varying survival
outcomes and there are several contradictions vis-á-vis post-
operative treatment. Several molecular factors have been and
are being considered currently to help selection of optimal
treatment [2–4].
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The role of β-catenin and E-cadherin proteins is well
known in cellular adhesion [5]. E-cadherin, a member of
the cell adhesion protein family, is a 120 kDa molecular
weight transmembrane glycoprotein encoded by the
CDH1 gene which is located on chromosome 16q22.
The extracellular domain interacts in a calcium dependent
mode with the E-cadherin molecules of neighbouring
cells. Intracellularly α, β and γ catenins form complexes
with E-cadherin and mediate linkage to the actin cyto-
skeleton. The cadherin-catenin complex is found at sites of
zonula adherentes. The p120 protein also interacts with
the intracellular domain of E-cadherin; however, the role
of this protein is not defined yet. Tumour cell dissociation
is an important step in the metastatic cascade. There is
ample evidence to prove that the diminished expression of
catenins and cadherins is critical in the metastatic cascade.
In addition to its role in cellular adhesion β-catenin
protein is also an important component of the so called
WNT signalling pathway [6, 7]. The non-degraded β-
catenin can translocate to the nucleus, where it acts as a
transcriptional activator in conjuction with the TcF/LEF
transcription molecule family. Thus it activates the
transcription of c-myc, cyclin D1, matrix metalloprotease
7 and CD44 genes [8]. The APC protein is a negative
regulator in the WNT signalling pathway. In physiological
conditions, in non-stimulated cells the APC/GSK3b/axin
destruction complex binds the cytoplasmic β-catenin
which becomes phosphorylated and eventually is degrad-
ed via the APC dependent ubiquitin-proteosome pathway
[9]. Mutations of the APC gene result in nuclear
accumulation of β-catenin, since these mutations allow
β-catenin to escape from the proteosomal degradation.
Subsequently, the nuclear translocation of β-catenin leads
to constitutive expression of the c-myc and cyclin D1
genes [8]. According to previous studies, the nuclear
accumulation of β-catenin and the reduced membranous
expression of E-cadherin play a key role in colorectal
tumour progression [10–12].
The aim of our study was to investigate the prognostic
significance of the expression of the β-catenin and E-
cadherin in Dukes B2 stage colorectal cancer immunohis-
tochemically. We intended to clarify whether and how
altered expression patterns of these proteins do influence
the metastatic potential of a given tumour.
This study population is Eastern-European (i.e., Hungarian)
and heretofore no such population has been analyzed and
reported on with regard to catenin-cadherin expression. All
patients had the same early stage (pT3) disease, and
received the same standardised adjuvant chemotherapy.
Our major goal was to determine if there is a difference in
β-catenin and E-cadherin expression between colon and
rectal tumours and if so, does that difference have any
functional/clinical significance. This seemed to be relevant
since previous similar studies did not separate these two,
anatomically different groups.
There is convincing literary evidence about the adequacy
of the sc. TMA method for investigating various prognostic
and predictive factors in many tumour types [13, 14].
Hence we opted for this methodology.
Materials and Methods
Patients and Specimens
Seventy-nine colorectal cancer cases were collected from
tissue archives of the Department of Pathology, University
of Debrecen, Medical & Health Sciences Centre [MHSC],
covering the time period of 5 years (1996–2001). The
fundamental selection criterion required that each tumour
had to belong to Dukes B2 stage (pT3N0 TNM stage). All
cases were selected using the original histopathology
reports. Clinical data were gathered from the MHSC
database on patients’ clinical records. The patients’ mean
age was 65.8 years (range: 35–85 years). The group
comprised of 39 women and 40 men. Mean follow-up time
was 52 months. All the patients with colon cancer received
standard postoperative 5-fluorouracil (5FU) adjuvant che-
motherapy, while patients with rectal tumour received
additional radiotherapy as well. None of the patients had
preoperative treatment. If metastatic disease was diagnosed
the patients received further chemotherapy. Three patients
died within 6 weeks following surgery, mainly of septic or
other complications. Other six patients had no follow-up
data. Data from these nine patients were not included in the
statistical analysis.
We divided the tumors into two groups according to the
tumours’ anatomical location: the colonic group included
tumours located anywhere from between the beginning of
the cecum to the sigmoid-rectal border. Tumors affecting
the large bowel’s most distal part comprised the “rectal
tumour group”. The clinicopathologic data are shown in
Table 1.
Tissue Microarray (TMA) Construction
Tumorous samples were formalin fixed and paraffin
embedded according to the Departmental routine protocol.
All cases were reviewed for confirmation of diagnosis.
Representative areas of paraffin blocks were identified on
corresponding HE stained slides. From the representative
areas 1 mm thick core biopsies were retrieved using a TMA
master (3DHistech Budapest, Hungary) and positioned in a
10×5 recipient paraffin array block. From all tumours 3-3
representative cores were obtained. A total of 237 cores
were built in TMA blocks from the 79 tumours. In 12 cases,
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one or both immunohistochemical reactions failed in two or
all three cores from the same tumour. These cores were
either lost or severely damaged. Some were nonrepresen-
tative due to necrosis or dominance of nonneoplastic tissue,
in other cases the IHC reaction(s) were unequivocal or
technically inadequate. From these tumour blocks new
cores were punched from other representative areas and a
new TMA block was built.
Immunohistochemistry (IHC)
Five micron sections from TMA blocks were used for
immunohistochemistry (IHC). The slides were deparaffi-
nated and rehydrated with xylol and graded alcohol.
Endogenous peroxidase activity was blocked with 0.5%
H2O2 for 30 min. Antigen retrieval was accomplished in
10 mM citrate buffer (pH 6.0) in a microwave at 600 W for
5 min. Nonspecific binding was blocked with 1% BSA for
10 min. Subsequently, the slides were incubated with the
primary antibody: β-catenin (Transduction Laboratories,
Lexington KY) clone C19220, 1:100 and E-cadherin
(Transduction Laboratories, Lexington KY) clone 36,
1:100 for 1 h, at 37°C. The slides were incubated with a
biotinylated rabbit antimouse immunoglobulin as second
antibody and subsequently treated with streptavidin perox-
idase conjugate for 30 min at 37C temperature and DAB
was used as chromogen substrate. After counterstaining
with haematoxylin, the slides were dehydrated and
mounted. Slides without the primary antibody were used
as negative controls.
IHC Scoring
The membranous and nuclear β-catenin expression (IHC
“decoration”) was evaluated separately. In case of E-
cadherin, only the membranous staining was considered
as positive. Normal colonic mucosa exhibited strong
membranous staining with both β-catenin and E-cadherin.
For both membranous and nuclear positivity of β-catenin
those cases in which <10% stained cells were observed the
result was classified as negative. If the decorated cells’
number fell between 11% and 50% staining was scored as:
1+. In those instances when positive staining occurred in
cells between 51% and 100% the score 2+ was given. For
E-cadherin if the number of decorated cells was <75% the
reaction was classified as “negative”. When the reactive
cells’ number fell between 76% and 90% the score was 1+;
staining of 91–100% of the cells scored 2+. Only those
cases with score 1+ and 2+ were considered as positive for
the purpose of statistical data analysis.
Statistical Analysis
The clinical outcome could fit into the 3-year disease free
survival (DFS) category and the 5-year overall survival
(OS) category. Associations between categorical factors
were studied with the Fisher exact test or the chi2 test as
appropriate. The rate of recurrence or death was estimated
using the Kaplan-Meier method. The multivariate logistic
Table 1 Clinicopathological data of the patients
Number of patients 79
Age 65.8 (35–85)
Sex
Male 40
Female 39
Tumour localisation
Right sided colon 19 (24.1%)
Left sided colon 29 (36.7%)
Rectum 31 (39.2%)
Grade
Well and moderately differentiated (G1-G2) 64 (81%)
Poorly differentiated (G3) 15 (19%)
Mean follow up time 52 months
5 year OS 59%
3 year DFS 64%
Fig. 1 a Membranous
β-catenin staining of normal
mucosa. b Membranous
E-cadherin staining of
normal mucosa
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regression analysis was applied to detect independent
metastasis development predictors. Statistical analysis was
performed using the SPSS 15.0 statistical package (Chicago,
IL). P<0.05 was considered as significant.
Results
Seventy-nine archival cases of Dukes B2 stage (pT3N0
TNM stage) colorectal cancer were analyzed. The 5-year
OS rate was 59% and the 3-year DFS rate was 64%. The
normal colonic mucosa exhibited strong membranous
staining with both β-catenin and E-cadherin (Fig. 1.).
Membranous expression of β-catenin was observed in 52
cases while 27 cases were negative (Fig. 2.). Nuclear
expression of β-catenin was detectable in 36 cases while 43
cases were negative (Fig. 3.). Membranous staining with E-
cadherin was observed in 46 cases, 33 cases were negative
(Fig. 4.). The expression profiles for both proteins are
shown in Table 2.
In the whole study population all those cases with
tumour cells showing membranous expression of β-catenin
had a better OS than those without it, however, this
difference was not statistically significant, p=0.280
(Fig. 5.). In case of DFS there was no difference, p=
0.442. The nuclear β-catenin expression or E-cadherin
expression did not stratify patients with regard to OS or
DFS. However, we observed that if either the β-catenin or
E-cadherin showed membranous staining, the OS was
better, compared to cases which were negative for both
reactions, however this result did not reach statistical
significance (p=0.492).
During the follow-up period 23 patients developed
metastatic disease. The risk of metastases was higher in
the β-catenin membranously negative group than in the
positive group. In light of the statistical analysis (p=0.062,
Table 3) this observation is best interpreted as a tendency
which needs further corroboration. When β-catenin showed
nuclear expression, the risk of metastases was higher and
this result was statistically significant, p=0.022. No
relationship between the expression of E-cadherin and
development of metastatic disease could be identified. If
neither β-catenin nor E-cadherin showed membranous
staining, the metastatic disease was significantly more
frequent, compared to cases in which both proteins
exhibited membranous expression, p=0.047.
Forty-eight patients had tumour in the right- or left side
of the colon. The patients’ mean age was 67.6 (range: 48–
83 years). Twenty-three women and 25 men were in this
group of patients. Thirty-nine tumours were well or
moderately differentiated while nine cases were poorly
differentiated. The clinical outcome was (statistically)
independent from β-catenin and E-cadherin expression
patterns.
Twelve patients had metastatic disease in this group.
There was no difference in the risk of metastases comparing
Fig. 3 Nuclear β-catenin staining of colon cancer
Fig. 2 Membranous β-catenin staining of colon cancer Fig. 4 E-cadherin staining of colon cancer
Table 2 β-catenin and E-cadherin staining and OS and DFS
Membranous
β-catenin
staining
Nuclear
β-catenin
staining
E-cadherin
staining
5 year
OS
3 year
DFS
All patients 65.8% 45.6% 58.2% 59% 64%
Colon group 72.3% 42.6% 61.7% 69% 73%
Rectum group 58.1% 51.6% 54.8% 42% 46%
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the groups with different protein expression patterns
(Table 4.).
Thirty-one patients had rectal tumour. The patients’
mean age was 63.1 (range: 35–85 year). Sixteen women
and 15 men were in this group of patients. Twenty-five
tumours were well or moderately differentiated while 6
cases were poorly differentiated. Membranous expression
of β-catenin was observed in 18 cases (58.1%), 13 cases
(41.9%) were negative. Nuclear expression of β-catenin
was detectable in 16 cases (51.6%), 15 cases (48.4%) were
negative (Fig. 3.). Membranous staining with E-cadherin
was observed in 17 cases (54.8%), 14 cases (45.2%) were
negative. Five-year OS was 42%, mean OS was
44.3 months. Three year DFS was 46%, mean DFS was
29.1 months. There was a trend towards improved DFS and
OS in patients with membranous β-catenin expression, but
it did not reach statistical significance, [p=0.087 and 0.085,
respectively] (Figs. 6 and 7). There was no difference in OS
and DFS either between nuclear β-catenin positive and
negative cases, or between E-cadherin positive and negative
patients.
In this group 11 patients had metastatic disease. The risk
of metastases was significantly higher in cases which were
β-catenin membranously negative than in those which were
membranously positive (p=0.024). When β-catenin
showed nuclear expression, the risk of metastases was also
significantly higher (p=0.047). No relational pattern could
be identified between the expression of E-cadherin and
development of metastatic disease (Table 5.).
Multivariate logistic regression analysis was carried out
with inclusion of patients’ age, tumour grade and local-
isation, E-cadherin/β-catenin membranous and nuclear
expression as statistical variables in order to identify those
parameters which could be important predictors for assess-
ing the risk of metastatic disease. Multivariate analysis did
not help to detect any additional significant correlations
between these variables compared to the results provided
by univariate analysis (Table 6).
Finally, we also established that in those patients with
metastatic disease (23 cases) there was a significantly better
DFS in those with positive membranous staining for β-
catenin than in the negative cases [36.58 months vs
14.55 months, respectively] (p=0.011). The OS was also
better in the group of positive membranous staining for β-
catenin (p=0.032). There was a trend towards improved
DFS and OS in patients with membranous E-cadherin
Fig. 5 Membranous β-catenin
staining and OS, all patients
Table 3 The development of
metastatic disease and β-catenin
and E-cadherin staining,
all patients
Statistical significance
(*) p<0.05
Metastatic disease Non metastatic disease P value
Membranous β-catenin staining 52.2% 74.4% 0.062
Nuclear β-catenin staining 65.2% 36.2% 0.022*
E-cadherin staining 52.2% 59.6% 0.369
E-cadherin and β-catenin membranous staining 26.1% 51% 0.047*.
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expression, but it was not significant statistically (29.5 months
vs 22.7 months respectively; p=0.851). The loss of membra-
nous β-catenin staining was associated with faster appear-
ance of metastases (27.16 months vs 13.18 months,
respectively; p=0.05). The loss of membranous staining of
E-cadherin also lead to faster appearance of metastases, but
this result was not statistically significant (24 months vs
16.63 months, respectively; p=0.16).
Discussion
The last two decades have witnessed a rapid accumulation
of studies aiming at the clarification of the exact role of β-
catenin and E-cadherin expression in colorectal carcino-
genesis. It is now believed that there are two pathogeneti-
cally distinct pathways for the development of colorectal
cancer [15]. Most cases are characterised by chromosomal
instability, the rest are featured by mutation(s) of the
mismatch repair genes and microsatellite instability. In the
first group, there is an accumulation of well known gene
defects during carcinogenesis. One of the most important
defects affects the APC-β-catenin system and this defect
seems to occur in the early stage of carcinogenesis. The
recently published results are neither uniform nor are they
consistent about the prognostic and predictive value of
these proteins. According to most reports, in case of
membranous staining of E-cadherin and β-catenin, better
survival can be expected and the occurrence of metastatic
disease is less common [16–20]. The nuclear expression of
β-catenin seems to have potentially adverse prognostic
significance in colorectal cancer [21].
From our results the following conclusions may be
drawn. Considering the total patient-population en masse,
the OS seems to be worse when the membranous
expression of the β-catenin is lost than in those cases
where it is retained. This difference, however, was not
statistically significant. In the whole population, the
development of metastatic disease is more frequent, when
the β-catenin membranous staining is lost. In case of
nuclear β-catenin staining, metastatic disease is also more
frequent, this correlation is significant.
Furthermore, by dividing the patients into two groups
according to the tumour localisation, additional remarkable
differences become obvious.
In the group of patients with colonic tumours, there is no
association between alterations of the expression of β-
catenin and E-cadherin on the one hand and OS or DFS on
the other. In these patients no difference in the risk of
metastases is detectable when comparing groups with
different β-catenin and E-cadherin expression patterns.
It is noteworthy that recent publications have empha-
sized a worse OS and DFS for patients with rectal cancer.
Table 4 The development of metastatic disease and β-catenin and E-
cadherin staining in the colon group
Metastatic
disease
Non metastatic
disease
P value
Membranous β-catenin staining 66.6% 71.8% 0.504
Nuclear β-catenin staining 58.3% 37.5% 0.184
E-cadherin staining 58.3% 59.4% 0.607
Fig. 6 Membranous β-catenin
staining and OS in
rectum group
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Hence we believe that our findings which confirm that the
loss of β-catenin and E-cadherin expression is more
common in this group does have clinical and biological
significance. Negativity of membranous staining of β-
catenin indicates worse OS. The difference in our study
although statistically is not significant, clearly indicates an
obvious susceptibility. Statistical significance may be
reached if additional cases can be recruited. The risk of
metastatic disease is significantly higher in the β-catenin
membranously negative cases than in the β-catenin mem-
branously positive rectal cancers. Our results implicate that
when β-catenin shows nuclear translocation, the risk of
metastases is also significantly higher and this strong
association likewise has clinical relevance.
We could also demonstrate that if neither β-catenin nor E-
cadherin show membranous staining, metastatic disease is
significantly more frequent, compared to the situation when
both proteins exhibit membranous expression.
Finally, we could also establish that in the group of
patients with metastatic disease the loss of membranous
staining of β-catenin leads to faster appearance of metas-
tases and DFS is also worse. The loss of membranous
staining of E-cadherin also seems to be associated with
rapidly evolving metastatic disease. Statistical significance
again may be arrived at by increasing the sample-number.
It is important to note that we could demonstrate
reliably strong association between IHC results and
clinical outcome only in the group of patients with
rectal cancer. For the rest of the patients only tendencies
seem to surface so far.
There are some notable discrepancies between our
findings and various reports already available. These
discrepancies might have a host of possible explanations.
Several previous studies investigated clinicopathologi-
cally inhomogeneous patient cohorts, including both early
or late stage tumors and a mixture of rectal- and colonic
cancers. Other authors strictly selected the cases and
investigated only stage I or II patients [22–24]. Moreover
Fig. 7 Membranous β-catenin
staining and DFS in
rectum group
Table 5 The development of metastatic disease and β-catenin and E-
cadherin staining in the rectum group
Metastatic
disease
Non metastatic
disease
P value
Membranous β-catenin staining 36.4% 80% 0.024*
Nuclear β-catenin staining 72.7% 33.3% 0.047*
E-cadherin staining 45.4% 60% 0.368
Statistical significance (*) p<0.05
Table 6 Multivariate analysis of the risks of metastasis, all patients
Sig. Exp (B) 95.0% C.I. for
Exp(B)
Lower Upper
Age 0,661 0,988 0,938 1,042
Grade 0,249 2,235 0,570 8,774
E-cadherin staining 0,970 1.022 0,332 3,140
Membranous β-catenin stainin 0,436 ,581 0,148 2,276
Nuclear β-catenin staining 0,222 2,256 0,611 8,321
Localisation 0,200 2,070 0,681 6,293
Constant 0,920 1,219
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one group studied only early stage rectal cancer patients
[25]. In our study we selected only early stage patients (i.
e., Dukes B2) who had not received any preoperative
treatment. Thus we consider our patient-cohort to be
clinicopathologically rather homogeneous.
We used the increasingly popular TMA method in our
study. This method was first described by Battifora [13],
then was improved by Koononen and co-workers [26, 27].
Recently a number of studies have demonstrated the
usefulness of this technique as a high throughput method
in tumour proteomic investigations [28, 29]. The TMA
method was also used by many working groups in the
investigation of colorectal cancer [14, 24, 25, 30]. Some
reports were published which studied the β-catenin- E-
cadherin complex this way [7, 31]. Some papers have
shown the validity of this method [32]. One of the problems
with the TMA method is that only a small part of the
tumours can be examined [12, 33]. We tried to avoid this
problem by the use of multiple cores from different
representative areas of the same tumour blocks.
In the previous reports we found no consistent scoring
system for the evaluation of the expression of β-catenin and
E-cadherin. Lack of standardisation of what constitutes
“positive” or “negative”, and the different cut-off value may
affect concordance between the results of various studies.
Next to the above described methodical and patient
selection differences within the complexity of colorectal
carcinogenesis can also explain the incoherent results.
According to different reports β-catenin and E-cadherin
both play a crucial role in cellular adhesion [5]. It is well
known that highly aggressive tumours, like signet ring
gastric cancer or lobular breast cancer usually do not
exhibit membranous E-cadherin expression [34, 35]. In
these cases the high metastatic potential is mostly due to the
loss of expression of E-cadherin. On the other hand tumour
cells which transgress vessel-walls and migrate via circu-
lation to distant sites also need adhesion molecules for
attachment. Indeed, the absence of adhesion molecules is an
advantage at the detachment of tumour cells, while, in
contrast, it is a drawback at homing.
Nuclear expression of β-catenin is also an important
event in colorectal carcinogenesis. The abnormality of the
β-catenin- APC system mostly can be detected and
generally so in early stage of tumorigenesis in the group
of colorectal tumours with chromosomal instability.
Certain studies provided evidence that there are impor-
tant genetic differences between the tumours of the right or
left colonic side vs the rectum [15, 36]. We have observed
correlations between the expression patterns of β-catenin/
E-cadherin complex and clinical outcomes in the group of
patients with rectal cancer.
In conclusion our results repeatedly confirm the critical
role of β-catenin and E-cadherin complex in colorectal
carcinogenesis. So far no specific targeted therapy acting
via these molecules is at hand. Furthermore, in case of
node-negative colorectal cancers, the necessity of adjuvant
treatment is not unequivocal. In Dukes B2 stage rectal
cancers the loss of membranous expression of β-catenin is
a predictor of the development of distant metastasis. Hence
we suggest, that in node negative patients with loss of β-
catenin membrane staining, adjuvant chemotherapy might
be considered necessary since the risk of metastatic spread
is increased.
Our results emphatically call for a possibly multi-
centred, large patient-pool based study. This requires a
clinicopathologically homogenous patient population, well
controlled IHC sampling and technique that can be
standardized. Only this approach can further clarify the
exact prognostic and predictive values of β-catenin and E-
cadherin expression in colorectal cancer.
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